# A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

> **NCT05442047** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 105 (actual)

## Conditions studied

- Transthyretin Amyloid Cardiomyopathy (ATTR CM)

## Interventions

- **DRUG:** NNC6019-0001
- **DRUG:** Placebo (NNC6019-0001)

## Key facts

- **NCT ID:** NCT05442047
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-02
- **Primary completion:** 2025-02-17
- **Final completion:** 2025-05-13
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05442047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05442047, "A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05442047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*